by Human platelet lysate is derived from platelets obtained from human blood donation. It is used as a substitute for animal serum in cell culture media. The growth factors and cytokines present in human platelet lysate promote cell growth and proliferation similar to animal serum. Human platelet lysate is increasingly being adopted for cell culture applications owing to its ability to support growth of mesenchymal stem cells, keratinocytes and other cell types while avoiding the risks of animal serum.
The global Human Platelet Lysate Market is estimated to be valued at US$ 53.0 Mn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rise in adoption of regenerative medicines is expected to drive the growth of the human platelet lysate market over the forecast period. Regenerative medicines involve utilization of stem cells for treatment of chronic diseases. As human platelet lysate is commonly used for isolation, cultivation, and growth of various types of stem cells including mesenchymal stem cells, its demand is anticipated to surge with the increasing scope of regenerative medicines.
SWOT Analysis
Strength: Human platelet lysate provides cost-effective alternative to fetal bovine serum. It is derived from blood donations from healthy adult donors making it safer choice.
Weakness: Production process of human platelet lysate is complex and requires specialized facilities. Supply challenges and inconsistencies in quality between batches.
Opportunity: Growing biopharmaceutical industry and stem cell research is driving the demand for serum-free cell culture media. Rising investment in regenerative medicine offers potential opportunities.
Threats: Stringent regulatory framework for production. Threat from other substitutes like platelet rich plasma and xenogeneic-free cell culture media.
Key Takeaways
The Global Human Platelet Lysate Market Demand is expected to witness high growth. Regional analysis comprises the North America region currently dominating the market due to favorable reimbursement policies and regulatory environment supporting adoption of regenerative medicine therapies. The Asia Pacific region is expected to be the fastest growing market over the forecast period owing to increasing investment in stem cell research.
Key players operating in the Human Platelet Lysate market are STEMCELL Technologies Inc., Merck KGaA, Mill Creek Life Sciences, Merck & Co., Inc, AventaCell BioMedical, Compass Biomedical, Inc, Macopharma SA, Trinova Biochem GmbH, PL BioScience GmbH, Cook Regentec, Life Science Group Ltd., BBI Solutions, Regenexx, Thermo Fisher Scientific. STEMCELL Technologies Inc., Merck KGaA are the leading players with significant market share. Companies are focused on expanding production capacity and capabilities to cater to the growing demand.
The global Human Platelet Lysate market size was valued at US$ 53.0 Mn in 2023 and is anticipated to reach US$ 74.3 Mn by 2030, registering a CAGR of 4.5% during the forecast period.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
